Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Diseas...
Maze Therapeutics, Inc. (MAZE)
Company Research
Source: GlobeNewswire
– At week 12, treatment with MZE829 resulted in a 35.6% mean uACR reduction in broad AMKD patients, 50% of the patients achieved a greater than 30% reduction in uACR, and treatment was well-tolerated – – The subgroup of AMKD patients with FSGS that were treated with MZE829 showed a 61.8% mean reduction in uACR – – Treatment of non-diabetic AMKD patients with MZE829 led to a clinically meaningful mean reduction in uACR from baseline of 48.6% – – Results provide first clinical proof-of-concept in genetically defined, broad AMKD population, including patients with moderate proteinuria and diabetes – – Maze plans to advance MZE829 to a pivotal program – – Maze to host investor conference call and webcast today at 8:00 am EDT – SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced
Show less
Read more
Impact Snapshot
Event Time:
MAZE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MAZE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MAZE alerts
High impacting Maze Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MAZE
News
- MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesGlobeNewswire
- Maze Therapeutics (MAZE) had its "buy" rating reaffirmed by BTIG Research. They now have a $46.00 price target on the stock.MarketBeat
- Maze Therapeutics (MAZE) had its price target raised by HC Wainwright from $60.00 to $110.00. They now have a "buy" rating on the stock.MarketBeat
- Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent HighlightsGlobeNewswire
- Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears [Yahoo! Finance]Yahoo! Finance
MAZE
Earnings
- 3/25/26 - Beat
MAZE
Sec Filings
- 3/25/26 - Form 10-K
- 3/25/26 - Form 8-K
- 3/20/26 - Form 4
- MAZE's page on the SEC website